Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 32823621 · doi:10.3390/nu12082435
What was done
Authors searched PubMed, Medline, and Embase through March 19, 2020, to identify randomized controlled trials evaluating resveratrol supplementation in non-alcoholic fatty liver disease (NAFLD). The meta-analysis pooled data from 7 RCTs comprising 302 patients. Resveratrol doses ranged from 500 mg to 3000 mg per day, administered over 56 to 180 days.
What was found
Resveratrol supplementation, irrespective of dose or duration, did not significantly affect analyzed NAFLD parameters. The only statistically significant finding was an increase in alanine aminotransferase (ALT) following resveratrol administration (p = 0.041). Exact effect sizes, confidence intervals, and specific non-significant numerical values were not reported in the abstract.
Why it matters
Despite proposed antioxidant and anti-inflammatory mechanisms, pooled clinical evidence does not support the efficacy of resveratrol supplementation as a treatment for NAFLD.
Limits
The total sample size across all seven trials was small (302 patients). The abstract omits numerical effect sizes, confidence intervals, heterogeneity statistics, and details on which specific parameters besides ALT were evaluated.
Cited by
- supports Pharmacological studies evaluating resveratrol typically use doses between 50 and 500 milligrams.